Jancke Georg, Rosell Johan, Jahnson Staffan
Department of Urology, University Hospital, Linköping, Sweden.
Scand J Urol Nephrol. 2011 Dec;45(6):388-92. doi: 10.3109/00365599.2011.590995. Epub 2011 Jun 16.
This study aimed to evaluate the impact of tumour size on recurrence and progression in a population-based series of non-muscle-invasive bladder cancers.
Clinical and pathological characteristics of patients with primary Ta/T1 bladder cancer were registered. The patients' tumours were categorized by size into five size groups (1-10, 11-20, 21-30, 31-40 and >40 mm) or three size groups (1-15, 16-30 and >30 mm).
The analysis included 768 evaluable patients with a mean follow-up of 60 months. Recurrence was observed in 478 patients (62%) and progression in 71 (9%). Tumour size was associated with recurrence for tumours sized 21?30, 31?40 and >40 mm (p = 0.03, p < 0.001, p < 0.001, respectively) in the five size group and for tumours sized 16?30 and >30 mm (p = 0.003 and p < 0.001) in the three size group. Other factors affecting recurrence were T1 tumour category, multiplicity and surgery performed by residents (p < 0.001, p < 0.001, p = 0.002, respectively). Considering progression, there was no significant association with tumour size, and T1 category and local recurrence were the only significant risk factors (both p < 0.001).
Tumour size ?15 mm is associated with a lower risk of recurrence but not progression. Dividing tumour size into three size groups gives additional information compared with two size groups with cut-off at 30 mm.
本研究旨在评估在一项基于人群的非肌层浸润性膀胱癌系列研究中肿瘤大小对复发和进展的影响。
记录原发性Ta/T1期膀胱癌患者的临床和病理特征。根据肿瘤大小将患者的肿瘤分为五个大小组(1 - 10、11 - 20、21 - 30、31 - 40和>40 mm)或三个大小组(1 - 15、16 - 30和>30 mm)。
分析纳入了768例可评估患者,平均随访60个月。478例患者(62%)出现复发,71例(9%)出现进展。在五个大小组中,肿瘤大小为21 - 30、31 - 40和>40 mm的肿瘤与复发相关(分别为p = 0.03、p < 0.001、p < 0.001),在三个大小组中,肿瘤大小为16 - 30和>30 mm的肿瘤与复发相关(p = 0.003和p < 0.001)。影响复发的其他因素是T1肿瘤类别、肿瘤多发以及住院医师进行的手术(分别为p < 0.001、p < 0.001、p = 0.002)。考虑进展情况,肿瘤大小与之无显著关联,T1类别和局部复发是仅有的显著危险因素(均为p < 0.001)。
肿瘤大小≤15 mm与较低的复发风险相关,但与进展无关。与以30 mm为界的两个大小组相比,将肿瘤大小分为三个大小组可提供更多信息。